Artificial pancreas: an emerging approach to treat Type 1 diabetes

References

• Guyton A, Hall J. Textbook of Medical Physiology. Elsevier Saunders, PA, USA (2006).
   Google Scholar
• Karvonen M, Viik-Kajander M, Moltchanova E et al. Incidence of childhood Type 1 diabetes worldwide. Diabetes Care23(10), 1516–1526 (2000).
   PubMed Web of Science ®Google Scholar
• Bessaoud K, Boudraa G, de Ropolo MM et al. Incidence and trends of childhood Type 1 diabetes worldwide 1990–1999. Diabet. Med.23(8), 857–866 (2006).
   Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med, 329(14), 977–986 (1993).
   PubMed Web of Science ®Google Scholar
• Pickup JC. Are insulin pumps underutilized in Type 1 diabetes? Yes. Diabetes Care29(6), 1449–1452 (2006).
   Google Scholar
• Pickup JC, Kidd J, Burmiston S, Yemane N. Determinants of glycaemic control in Type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabetes Metab. Res. Rev.22(3), 232–237 (2006).
   Google Scholar
• Bruttomesso D, Costa S, Baritussio A. Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy. Diabetes Metab. Res. Rev.25(2), 99–111 (2009).
   PubMed Web of Science ®Google Scholar
• Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with Type 1 diabetes: meta-analysis of randomised controlled trials. Br. Med. J.324(7339), 705–708 (2002).
   PubMed Web of Science ®Google Scholar
• Pickup JC, Renard E. Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and Type 2 diabetes. Diabetes Care31(Suppl. 2), S140–S145 (2008).
   PubMed Web of Science ®Google Scholar
• Pickup JC, Hammond P. NICE guidance on continuous subcutaneous insulin infusion 2008: review of the technology appraisal guidance. Diabet. Med.26(1), 1–4 (2009).
   Google Scholar
• Selam JL. External and implantable insulin pumps: current place in the treatment of diabetes. Exp. Clin. Endocrinol. Diabetes109, S333–S340 (2001).
   PubMed Web of Science ®Google Scholar
• Renard E. Implantable closed-loop glucose-sensing and insulin delivery: the future for insulin pump therapy. Curr. Opin. Pharmacol.2(6), 708–716 (2002).
   PubMed Web of Science ®Google Scholar
• Renard E, Schaepelynck-Bélicar P; the EVADIAC Group. Implantable insulin pumps. A position statement about their clinical use. Diabetes Metab.33(2), 158–166 (2007).
   PubMed Web of Science ®Google Scholar
• Gin H, Renard E, Melki V et al. Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in Type 1 diabetic patients: the EVADIAC experience. Diabetes Metab.29(6), 602–607 (2003).
   PubMed Web of Science ®Google Scholar
• Renard E, Costalat G, Chevassus H, Bringer J. Closed loop insulin delivery using implanted insulin pumps and sensors in Type 1 diabetic patients. Diabetes Res. Clin. Pract.74, S173–S177 (2006).
   Google Scholar
• Shapiro AMJ, Lakey JRT, Ryan EA et al. Islet transplantation in seven patients with Type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med.343(4), 230–238 (2000).
   PubMed Web of Science ®Google Scholar
• Ryan EA, Paty BW, Senior PA et al. Five-year follow-up after clinical islet transplantation. Diabetes54(7), 2060–2069 (2005).
   PubMed Web of Science ®Google Scholar
• Jones PM, Courtney ML, Burns CJ, Persaud SJ. Cell-based treatments for diabetes. Drug Discov. Today13(19–20), 888–893 (2008).
   Google Scholar
• Wojcicki JM, Ladyzynski P. Toward the improvement of diabetes treatment: recent developments in technical support. J. Artif. Organs6(2), 73–87 (2003).
   PubMedGoogle Scholar
• Farmer TG, Edgar TF, Peppas NA. The future of open- and closed-loop insulin delivery systems. J. Pharm. Pharmacol.60(1), 1–13 (2008).
   PubMed Web of Science ®Google Scholar
• Kadish AH. Automation control of blood sugar. I. Servomechanism for glucose monitoring and control. Am. J. Med. Electron.3(2), 82–86 (1964).
   PubMedGoogle Scholar
• Clemens AH, Chang PH, Myers RW. The development of Biostator, a Glucose Controlled Insulin Infusion System (GCIIS). Horm. Metab. Res. Suppl. 7, 23–33 (1977).
   Google Scholar
• Clarke WL, Cox D, Gonderfrederick LA, Carter W, Pohl SL. Evaluating clinical accuracy of systems for self-monitoring of blood-glucose. Diabetes Care10(5), 622–628 (1987).
   PubMed Web of Science ®Google Scholar
• Kovatchev B, Anderson S, Heinemann L, Clarke W. Comparison of the numerical and clinical accuracy of four continuous glucose monitors. Diabetes Care31(6), 1160–1164 (2008).
   PubMed Web of Science ®Google Scholar
• Kovatchev BP, Gonder-Frederick LA, Cox DJ, Clarke WL. Evaluating the accuracy of continuous glucose-monitoring sensors. Diabetes Care27(8), 1922–1928 (2004).
   PubMed Web of Science ®Google Scholar
• Mastrototaro J. The MiniMed Continuous Glucose Monitoring System (CGMS). J. Pediatr. Endocrinol. Metab.12, 751–758 (1999).
   PubMed Web of Science ®Google Scholar
• Rebrin K, Steil GM, Van Antwerp WP, Mastrototaro JJ. Subcutaneous glucose predicts plasma glucose independent of insulin: implications for continuous monitoring. Am. J. Physiol. Endocrinol. Metab.277(3), E561–E571 (1999).
   PubMed Web of Science ®Google Scholar
• Sachedina N, Pickup JC. Performance assessment of the Medtronic-MiniMed Continuous Glucose Monitoring System and its use for measurement of glycaemic control in Type 1 diabetic subjects. Diabet. Med.20(12), 1012–1015 (2003).
   PubMed Web of Science ®Google Scholar
• Garg S, Jovanovic L. Relationship of fasting and hourly glucose levels to HbA(1c) values blood. Diabetes Care29(12), 2644–2649 (2006).
   PubMed Web of Science ®Google Scholar
• Mastrototaro J, Soundararajan G, Cooper K, Shah R. Accuracy of real-time continuous glucose monitoring in the MiniMed paradigm system. Diabetes56, A112 (2007).
   Google Scholar
• Wilson DM, Beck RW, Tamborlane WV et al. The accuracy of the FreeStyle Navigator continuous glucose monitoring system in children with Type 1 diabetes. Diabetes Care30(1), 59–64 (2007).
   PubMed Web of Science ®Google Scholar
• Hirsch IB, Armstrong D, Bergenstal RM et al. Clinical application of emerging sensor technologies in diabetes management: consensus guidelines for continuous glucose monitoring (CGM). Diabetes Technol. Ther.10(4), 232–244 (2008).
   PubMed Web of Science ®Google Scholar
• Tamborlane WV, Beck RW, Bode BW et al.; the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of Type 1 diabetes. N. Engl. J. Med.359(14), 1464–1476 (2008).
   PubMed Web of Science ®Google Scholar
• Hirsch IB, Abelseth J, Bode BW et al. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol. Ther.10(5), 377–383 (2008).
   PubMed Web of Science ®Google Scholar
• Hovorka R. The future of continuous glucose monitoring: closed loop. Curr. Diabetes Rev.4(3), 269–279 (2008).
   PubMedGoogle Scholar
• Buckingham B, Block J, Burdick J et al. Response to nocturnal alarms using a real-time glucose sensor. Diabetes Technol. Ther.7(3), 440–447 (2005).
   Google Scholar
• Bequette BW. A critical assessment of algorithms and challenges in the development of a closed-loop artificial pancreas. Diabetes Technol. Ther.7(1), 28–47 (2005).
   PubMedGoogle Scholar
• Steil GM, Panteleon AE, Rebrin K. Closed-loop insulin delivery – the path to physiological glucose control. Adv. Drug Deliv. Rev.56(2), 125–144 (2004).
   PubMed Web of Science ®Google Scholar
• Hovorka R, Canonico V, Chassin LJ et al. Nonlinear model predictive control of glucose concentration in subjects with Type 1 diabetes. Physiol. Meas.25(4), 905–920 (2004).
   PubMed Web of Science ®Google Scholar
• Schaller HC, Schaupp L, Bodenlenz M et al. On-line adaptive algorithm with glucose prediction capacity for subcutaneous closed loop control of glucose: evaluation under fasting conditions in patients with Type 1 diabetes. Diabet. Med.23(1), 90–93 (2006).
   PubMed Web of Science ®Google Scholar
• Dassau E, Bequette BW, Buckingham BA, Doyle FJ. Detection of a meal using continuous glucose monitoring: implications for an artificial b-cell. Diabetes Care31(2), 295–300 (2008).
   PubMed Web of Science ®Google Scholar
• Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabet. Med.23(1), 1–12 (2006).
   PubMed Web of Science ®Google Scholar
• Plank J, Wutte A, Brunner G et al. A direct comparison of insulin aspart and insulin lispro in patients with Type 1 diabetes. Diabetes Care25(11), 2053–2057 (2002).
   PubMed Web of Science ®Google Scholar
• Hovorka R, Shojaee-Moradie F, Carroll PV et al. Partitioning glucose distribution/transport, disposal, and endogenous production during IVGTT. Am. J. Physiol. Endocrinol. Metab.282(5), E992–E1007 (2002).
   PubMed Web of Science ®Google Scholar
• Albisser AM, Leibel BS, Ewart TG, Davidova Z, Botz CK, Zingg W. Artificial endocrine pancreas. Diabetes23(5), 389–396 (1974).
   PubMed Web of Science ®Google Scholar
• Pfeiffer EF, Thum C, Clemens AH. Artificial b cell – continuous control of blood-sugar by external regulation of insulin infusion. Horm. Metab. Res.6(5), 339–342 (1974).
   PubMed Web of Science ®Google Scholar
• Pfeiffer EF. The glucose sensor: the missing link in diabetes therapy. Horm. Metab. Res. Suppl.24, 154–164 (1990).
   Google Scholar
• Selam JL, Charles MA. Devices for insulin administration. Diabetes Care13(9), 955–979 (1990).
   PubMed Web of Science ®Google Scholar
• Goriya Y, Kawamori R, Shichiri M, Abe H. Development of an aritficial b-cell system and its validation in depancreatized dogs – physiological restoration of blood-glucose homestasis. Med. Prog. Technol.6(3), 99–108 (1979).
   Google Scholar
• Shichiri M, Kawamori R, Yamasaki Y, Hakui N, Abe H. Wearable artificial endocrine pancreas with needle-type glucose sensor. Lancet2(8308), 1129–1131 (1982).
   PubMed Web of Science ®Google Scholar
• Shimoda S, Nishida K, Sakakida M et al. Closed-loop subcutaneous insulin infusion algorithm with a short-acting insulin analog for long-term clinical application of a wearable artificial endocrine pancreas. Front. Med. Biol. Eng.8(3), 197–211 (1997).
   Google Scholar
• Shimoda S, Nishida K, Sakakida M, Matsuo Y, Araki E. Development of closed-loop intraperitoneal insulin infusion algorithm for a implantable artificial endocrine pancreas. Diabetes50, A3 (2001).
   Google Scholar
• Steil GM, Rebrin K, Janowski R, Darwin C, Saad MF. Modeling b-cell insulin secretion – implications for closed-loop glucose homeostasis. Diabetes Technol. Ther.5(6), 953–964 (2003).
   PubMedGoogle Scholar
• Panteleon AE, Loutseiko M, Steil GM, Rebrin K. Evaluation of the effect of gain on the meal response of an automated closed-loop insulin delivery system. Diabetes55(7), 1995–2000 (2006).
   PubMed Web of Science ®Google Scholar
• Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of Type 1 diabetes. Diabetes55(12), 3344–3350 (2006).
   PubMed Web of Science ®Google Scholar
• Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus sermautomated hybrid control in pediatric patients with Type 1 diabetes using an artificial pancreas. Diabetes Care31(5), 934–939 (2008).
   PubMed Web of Science ®Google Scholar
• Hovorka R, Chassin LJ, Wilinska ME et al. Closing the loop: the ADICOL experience. Diabetes Technol. Ther.6(3), 307–318 (2004).
   PubMedGoogle Scholar
• Galley P, Wagner R, Buck H et al. Use of subcutaneous continuous glucose measurements to drive real-time algorithm-directed insulin infusion recommendations. Diabetes Technol. Ther.6, 245–246 (2004).
   Google Scholar
• Hovorka R, Acerini CL, Allen J et al. Overnight sc–sc closed-loop control improves glucose control and reduces risk of hypoglycaemia in children and adolescents with Type 1 diabetes. Diabetes57, A22 (2008).
   Google Scholar
• Hovorka R, Acerini CL, Allen J et al. Good overnight closed-loop glucose control in children and adolescents with Type 1 diabetes following ingestion of large, rapidly and slowly absorbed evening meat. Diabetologia51, 181 (2008).
   Google Scholar
• Buckingham B, Cobry E, Clinton P et al. Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Technol. Ther.11(2), 93–97 (2009).
   PubMed Web of Science ®Google Scholar
• Radermecker RP, Scheen AJ. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost–effectiveness. Diabetes Metab. Res. Rev.20(3), 178–188 (2004).
   Google Scholar
• Zisser H. Quantifying the impact of a short-interval interruption of insulin-pump infusion sets on glycemic excursions. Diabetes Care31(2), 238–239 (2008).
   Google Scholar
• El-Khatib FH, Jiang J, Gerrity RG, Damiano ER. Pharmacodynamics and stability of subcutaneously infused glucagon in a Type 1 diabetic swine model in vivo. Diabetes Technol. Ther.9(2), 135–144 (2007).
   Google Scholar
• El-Khatib F, Jiang JX, Damiano E. Adaptive closed-loop control provides robust blood-glucose regulation using dual subcutaneous insulin and glucagon infusion in ambulatory diabetic swine. Diabetes56, A125 (2007).
   Google Scholar
• Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with Type 2 diabetes mellitus. Horm. Metab. Res.34(9), 504–508 (2002).
   PubMed Web of Science ®Google Scholar
• Heptulla RA, Rodriguez LM, Bomgaars L, Haymond MW. The role of amylin and glucagon in the dampening of glycemic excursions in children with Type 1 diabetes. Diabetes54(4), 1100–1107 (2005).
   PubMed Web of Science ®Google Scholar
• Kovatchev B, Raimondo D, Breton M, Patek S, Cobelli C. In silico testing and in vivo experiments with closed-loop control of blood glucose in diabetes. Presented at: 17th International Federation of Automatic Control (IFAC) World Congress. Seoul, South Korea, 6–11 July 2008.
   Google Scholar
• Chassin LJ, Wilinska ME, Hovorka R. Evaluation of glucose controllers in virtual environment: methodology and sample application. Artif. Intell. Med.32(3), 171–181 (2004).
   PubMed Web of Science ®Google Scholar
• Kovatchev B, Breton M, Dalla Man C, Cobelli C. In silico preclinical trials: a proof of concept in closed-loop control of Type 1 diabetes. J. Diabetes Sci. Technol.3(1), 43–55 (2009).
   Google Scholar
• Man CD, Rizza RA, Cobelli C. Meal simulation model of the glucose–insulin system. IEEE Trans. Biomed. Eng.54, 1740–1749 (2007).
   Google Scholar
• Fabietti PG, Canonico V, Orsini-Federici M, Sarti E, Massi-Benedetti M. Clinical validation of a new control-oriented model of insulin and glucose dynamics in subjects with Type I diabetes. Diabetes Technol. Ther.9(4), 327–338 (2007).
   PubMed Web of Science ®Google Scholar
• Norhammar A, Tenerz A, Nilsson G et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet359(9324), 2140–2144 (2002).
   PubMed Web of Science ®Google Scholar
• Van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in critically ill patients. N. Engl. J. Med.345(19), 1359–1367 (2001).
   PubMed Web of Science ®Google Scholar
• Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults – a meta-analysis. JAMA300(8), 933–944 (2008).
   PubMed Web of Science ®Google Scholar
• Finfer S, Chittock DR, Su SY et al.; NICE-SUGAR study investigators. Intensive versus conventional glucose control in critically ill patients. N. Engl. J. Med.360(13), 1283–1297 (2009).
   PubMed Web of Science ®Google Scholar
• Chee F, Fernando T, van Heerden PV. Closed-loop glucose control in critically ill patients using continuous glucose monitoring system (CGMS) in real time. IEEE Trans. Inf. Technol. Biomed.7(1), 43–53 (2003).
   Google Scholar
• Plank J, Blaha J, Cordingley J et al. Multicentric, randomized, controlled trial to evaluate blood glucose control by the model predictive control algorithm versus routine glucose management protocols in intensive care unit patients. Diabetes Care29(2), 271–276 (2006).
   Google Scholar